Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to $12.1 million.

  • Niagen Bioscience's Cost of Revenue rose 2910.06% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 2740.37%. This contributed to the annual value of $38.0 million for FY2024, which is 1592.25% up from last year.
  • Latest data reveals that Niagen Bioscience reported Cost of Revenue of $12.1 million as of Q3 2025, which was up 2910.06% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Cost of Revenue ranged from a high of $12.1 million in Q3 2025 and a low of $6.3 million during Q1 2021
  • In the last 5 years, Niagen Bioscience's Cost of Revenue had a median value of $8.3 million in 2023 and averaged $8.6 million.
  • In the last 5 years, Niagen Bioscience's Cost of Revenue skyrocketed by 4344.29% in 2021 and then plummeted by 1752.11% in 2022.
  • Niagen Bioscience's Cost of Revenue (Quarter) stood at $8.6 million in 2021, then decreased by 17.52% to $7.1 million in 2022, then rose by 15.88% to $8.3 million in 2023, then skyrocketed by 32.32% to $10.9 million in 2024, then rose by 10.34% to $12.1 million in 2025.
  • Its Cost of Revenue was $12.1 million in Q3 2025, compared to $10.9 million in Q2 2025 and $11.2 million in Q1 2025.